


# HIV in the U.S. by the Numbers – Current Year

This fact sheet includes CDC’s latest national estimates of new HIV infections (HIV incidence) and the total number of people estimated to have HIV (HIV prevalence) in the United States. Also included are the latest estimates for several indicators of progress in HIV prevention and treatment, including pre-exposure prophylaxis (PrEP) use, linkage to care, and viral suppression. State- and city-level HIV data are available [here](#).

Because there are gaps in epidemiology data for HIV among transgender women, this fact sheet includes the best available data on HIV incidence, prevalence, PrEP use, and receipt of medical care and treatment for this population from CDC’s [National HIV Behavioral Surveillance](#) .


For more information on the current state of the HIV epidemic, [click here](#) .

Table 1. New HIV Infections, 2019 

New HIV Infections, 2019	Number	Rate <sup>a</sup>
<b>Age</b>		
13-24	7,200 <sup>f</sup>	20.7
25-34	13,800	39.7
35-44	6,900	19.8
45-54	3,800 <sup>f</sup>	10.9
55+	3,100	8.9
<b>Race/Ethnicity</b>		
Black/African American	14,300	41.1
Hispanic/Latino <sup>b</sup>	10,200	29.3
White	8,600	24.7
Multiple Races	900 <sup>f</sup>	2.6
Asian	550	1.6
American Indian/Alaska Native	*230	0.66
Native Hawaiian/Other Pacific Islander	...	...
<b>Transmission Category<sup>c</sup></b>		
Gay and bisexual men	23,100 <sup>f</sup>	66.4
Heterosexual people <sup>d</sup>	7,800	22.4
People who inject drugs	2,500	7.2

New HIV Infections, 2019	Number	Rate <sup>a</sup>
Gay and bisexual men who inject drugs	1,400	4
<b>Region of Residence<sup>g</sup></b>		
Northeast	4,700	13.5
Midwest	4,500	12.9
South	18,500	53.2
West	7,100	20.4
<b>Total<sup>e</sup></b>	<b>34,800<sup>f</sup></b>	<b>--</b>

Source: Table 1 in CDC. Estimated HIV incidence and prevalence in the United States, 2015-2019. *HIV Surveillance Supplemental Report 2021;26(No. 1)*  . Published May 2021. Accessed September 2021.

Abbreviation: RSE, relative standard error; CDC4, CDC4+T-lymphyte count (cells/ $\mu$ L) or percentage [footnotes only].

Note: Estimates derived by using HIV surveillance and CD4 data for people ages  $\geq 13$  at diagnosis. Estimates rounded to the nearest 100 for estimates  $< 1,000$  and to the nearest 10 for estimates of  $\leq 1,000$  to reflect model uncertainty. Estimates with an RSE of 30%–50% are designated by an asterisk (\*) and should be interpreted with caution. Estimates with an RSE of  $> 50\%$  are statistically unreliable, not shown, and are replaced by an ellipsis (...).

a Rates are per 100,000 population. Rates are not calculated for transmission category because of the lack of the denominator data.



b Hispanic/Latino people can be of any race.

c Data by transmission category have been statistically adjusted to account for missing risk-factor information.

d Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

e Includes persons with HIV infection attributed to hemophilia or blood transfusion, or whose risk factor was not reported or identified.

f Indicates that difference from 2015 estimate was deemed statistically significant ( $P < .05$ ).

g The four regions of residence used in this report were defined by the U.S. Census Bureau  .

Showing 1 to 30 of 30 entries

Table 2. People with HIV (Includes Total Number Diagnosed and Undiagnosed Combined), 2019 

People with HIV (Includes Total Number Diagnosed and Undiagnosed Combined), 2019	Number	Rate <sup>a</sup>
<b>Age</b>		
13-24	45,900	90.0
25-34	218,700	476.0
35-44	228,000	547.3
45-54	290,000	709.4
55+	407,100	421.8
<b>Race/Ethnicity</b>		
American Indian/Alaska Native	4,000	200.8
Asian <sup>b</sup>	17,700	108.5
Black/African American	479,300	1411.4
Hispanic/Latino <sup>c</sup>	294,200	625.8
Native Hawaiian/Other Pacific Islander	1,100	221.1

People with HIV (Includes Total Number Diagnosed and Undiagnosed Combined), 2019	Number	Rate <sup>a</sup>
White	338,600	197.6
Multiple Races	54,100	1113.4
<b>Transmission Category<sup>d</sup></b>		
Male-to-male sexual contact	692,900	-
Injection drug use	124,700	-
Male-to-male sexual contact and injection drug use	61,800	-
Heterosexual contact <sup>e</sup>	307,000	-
<b>Region of Residence<sup>g</sup></b>		
Northeast	253,600	530.5
Midwest	145,100	252.9
South	551,600	524.4
West	239,400	364.7
<b>Total</b>	<b>1,189,700<sup>f</sup></b>	<b>431.0</b>

Source: Table 8 in CDC. Estimated HIV incidence and prevalence in the United States, 2015-2019. *HIV Surveillance Supplemental Report 2021;26(No. 1)* . Published May 2021. Accessed September 2021.

Abbreviation: RSE, relative standard error; CDC4, CDC4+T-lymphyte count (cells/ $\mu$ L) or percentage [footnotes only].

Note: Estimates derived by using HIV surveillance and CD4 data for people ages  $\geq 13$  at diagnosis. Estimates rounded to the nearest 100 for estimates  $< 1,000$  and to the nearest 10 for estimates of  $\leq 1,000$  to reflect model uncertainty. Estimates with an RSE of 30%–50% are designated by an asterisk (\*) and should be interpreted with caution.

a Rates are per 100,000 population. Rates are not calculated for transmission category because of the lack of the denominator data.


b Includes Asian/Pacific Islander cases.

c Hispanic/Latino people can be of any race.

d Data by transmission category have been statistically adjusted to account for missing risk-factor information.

e Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

f Includes persons with HIV infection attributed to hemophilia or blood transfusion, or whose risk factor was not reported or identified.

g The four regions of residence used in this report were defined by the U.S. Census Bureau  .

Showing 1 to 30 of 30 entries

### Table 3. HIV-Related Deaths through 2019

HIV-Related Deaths, through 2019	Number
Cumulative	551,779

Source: CDC National Center for Health Statistics

Note: Data for the year 2019 are preliminary and based on deaths reported to CDC as of December 2020.

Showing 1 to 1 of 1 entries

### Table 4. Pre-Exposure Prophylaxis Use, 2019

Pre-Exposure Prophylaxis Coverage, 2019	Number of People with PrEP Indications <sup>a</sup>	Number (%) of People Using PrEP <sup>b c</sup>
<b>Age</b>		
16-24	246,290	37,244 (15.1)
25-34	434,680	109,593 (25.2)
35-44	238,470	62,374 (26.2)
45-54	173,420	36,273 (20.9)
55+	123,350	23,538 (19.1)
<b>Race/Ethnicity<sup>d</sup></b>		
Black/African American	468,540	36,578 (7.8)
Hispanic/Latino <sup>e</sup>	312,820	42,270 (13.5)
Other	131,180	11,423 (8.7)
White	300,650	178,834 (59.5)
<b>Total</b>	<b>1,216,210</b>	<b>269,106 (22.1)</b>

Source: Table 3a in CDC. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through March 2021; and Pre-exposure prophylaxis data reported through December 2020. *HIV Surveillance Data Tables 2021; 2 (No. 3)*. Published July 2021. Accessed November 2021. Abbreviation: PrEP, pre-exposure prophylaxis.

Note: PrEP coverage is not a reportable disease or condition and is not reported to the National HIV Surveillance System. Multiple data sources are used to calculate PrEP coverage, and data are not currently available by transmission category or region of residence.

<sup>a</sup> Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. The 2018 denominators were used for 2019 PrEP coverage data.


<sup>b</sup> Estimated by using data from IQVIA pharmacy database reported through December 2020 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of people who had indications for PrEP.

<sup>d</sup> Race/ethnicity data were only available for <40% of persons prescribed PrEP in 2019. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted by applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

<sup>e</sup> Hispanic/Latino people can be of any race.

Showing 1 to 14 of 14 entries

Table 5. Linkage to HIV Medical Care and Viral Suppression Within Six Months of HIV Diagnosis, 2019 

Linkage to HIV Medical Care and Viral Suppression Within Six Months of HIV Diagnosis, 2019	Total Number Diagnosed	Number (%) of Linkage to Care Within One Month	Number (%) of Viral Suppression Within Six Months
<b>Age</b>			

Linkage to HIV Medical Care and Viral Suppression Within Six Months of HIV Diagnosis, 2019	Total Number Diagnosed	Number (%) of Linkage to Care Within One Month	Number (%) of Viral Suppression Within Six Months
13-24	7,093	5,602 (79.0)	4,835 (68.2)
25-34	12,105	9,775 (80.8)	8,223 (67.9)
35-44	6,560	5,405 (82.4)	4,517 (68.9)
45-54	4,523	3,767 (83.3)	3,121 (69.0)
55+	3,514	2,930 (83.4)	2,386 (67.9)
<b>Race/Ethnicity</b>			
American Indian/Alaska Native	206	172 (83.5)	132 (64.1)
Asian	687	570 (83.0)	523 (76.1)
Black/African American	14,268	11,179 (78.4)	9,309 (65.2)
Hispanic/Latino <sup>a</sup>	9,478	8,004 (84.4)	6,768 (71.4)
Native Hawaiian/Other Pacific Islander	66	53 (80.3)	46 (69.7)
White	8,249	6,817 (82.6)	5,726 (69.4)
Multiple Races	841	684 (81.3)	578 (68.7)
<b>Transmission Category<sup>b</sup></b>			
Gay and bisexual men	22,392	18,839 (82.1)	15,634 (69.8)
People who inject drugs	2,175	1,640 (75.4)	1,187 (54.6)
Gay and bisexual men who inject drugs	1,347	1,080 (80.2)	872 (64.7)
Heterosexual people <sup>c</sup>	7,821	6,320 (80.8)	5,344 (68.3)
<b>Total<sup>d</sup></b>	<b>33,795</b>	<b>27,479 (81.3)</b>	<b>23,082 (68.3)</b>

Source: Table 2a in CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019. *HIV Surveillance Supplemental Report 2021;26(No. 2)* . Published May 2021. Accessed September 2021.

Note: Data are based on residence at time of diagnosis. Linkage to HIV medical care was measured by documentation of  $\geq 1$  CD4 or VL tests  $\leq 1$  month or  $\geq 3$  months after HIV diagnosis. A VL test result of  $< 200$  copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2019. Data not provided for states and associated countries that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and the six dependent areas – American Samoa, Guam, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands.

<sup>a</sup> Hispanic/Latinos can be of any race.

<sup>b</sup> Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented on sex at birth and include transgender persons.


<sup>c</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>d</sup> Includes persons whose infection was attributable to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or identified. Data not displayed because the numbers were too small to be meaningful.

Showing 1 to 23 of 23 entries



Proportion of Transgender Women with HIV	Number (%) of Participants with HIV <sup>b</sup>	Total Number of Survey Participants
<b>Age</b>		
18-24	26 (14.1)	184
25-29	99 (33.1)	299
30-39	193 (43.3)	446
40-49	149 (50.7)	294
50+	192 (57.0)	337
<b>Race/Ethnicity</b>		
American Indian/Alaska Native	11 (64.7)	17
Asian	6 (20.0)	30
Black/African American	339 (61.9)	548
Hispanic/Latina <sup>c</sup>	219 (35.0)	626
Native Hawaiian/Other Pacific Islander	7 (16.7)	42
White	30 (17.0)	176
Multiple Races	45 (37.8)	119
<b>Total</b>	<b>659 (42.2)</b>	<b>1,561</b>

Source: Table 2 in CDC. HIV Infection, Risk, Prevention, and Testing Behaviors Among Transgender Women—National HIV Behavioral Surveillance, 7 U.S. Cities, 2019–2020. *HIV Surveillance Special Report 27*  . Published April 2021. Accessed September 2021. Abbreviation: NHBS, National Behavioral Surveillance [footnotes only].


Note: Data include participants with a valid NHBS HIV test result.

<sup>a</sup> The seven U.S. cities in this report included Atlanta, GA; Los Angeles, CA; New Orleans, LA; New York City, NY; Philadelphia, PA; San Francisco, CA; and Seattle, WA.

<sup>b</sup> Participants with a reactive rapid NHBS HIV test result supported by a second rapid test or supplemental laboratory-based testing.

<sup>c</sup> Hispanics/Latinas can be of any race.

Showing 1 to 17 of 17 entries

Table 7. Pre-Exposure Prophylaxis Use Among Transgender Women —National HIV Behavioral Surveillance, 7 U.S. Cities, 2019-2020<sup>a</sup> 

Pre-Exposure Prophylaxis Use Among Transgender Women with HIV	Total Number of Survey Participants <sup>b</sup>	Number (%) Who Used PrEP <sup>c</sup>
<b>Age</b>		
18-24	158	53 (33.5)

Pre-Exposure Prophylaxis Use Among Transgender Women with HIV	Total Number of Survey Participants <sup>b</sup>	Number (%) Who Used PrEP <sup>c</sup>
25-29	200	70 (35.0)
30-39	253	84 (33.2)
40-49	145	54 (37.2)
50+	145	26 (17.9)
Race/Ethnicity		
American Indian/Alaska Native	6	4 (66.7)
Asian	24	6 (25.0)
Black/African American	209	64 (30.6)
Hispanic/Latina <sup>d</sup>	407	150 (36.9)
Native Hawaiian/Other Pacific Islander	35	4 (11.4)
White	146	33 (22.6)
Multiple Races	74	27 (36.5)
Total	902	288 (31.9)

Source: Table 6a in CDC. *HIV Infection, Risk, Prevention, and Testing Behaviors Among Transgender Women—National HIV Behavioral Surveillance, 7 U.S. Cities, 2019–2020. HIV Surveillance Special Report 27*. Published April 2021. Accessed September 2021. Abbreviations: NHBS, National HIV Behavioral Surveillance; PrEP, pre-exposure prophylaxis.

<sup>a</sup> The seven U.S. cities in this report included Atlanta, GA; Los Angeles, CA; New Orleans, LA; New York City, NY; Philadelphia, PA; San Francisco, CA; and Seattle, WA.

<sup>b</sup> Participants with a valid negative NHBS HIV test result.

<sup>c</sup> Took PrEP at any point in the 12 months before interview to reduce the risk of getting HIV.


<sup>d</sup> Hispanics/Latinas can be of any race.

Showing 1 to 18 of 18 entries

Table 8. Receipt of HIV Care and Treatment Among Self-Reported HIV-Positive Transgender Women — National HIV Behavioral Surveillance, 7 U.S. Cities, 2019-2020<sup>a</sup>

Receipt of HIV Care and Treatment Among Self-Reported HIV-Positive Transgender Women	Total Number of Survey Participants <sup>b</sup>	Number (%) Who Visited Health Care Provider About HIV Within One Month After Diagnosis	Number (%) Who Are Currently Taking Antiretrovirals
<b>Age</b>			
18-24	25	16 (64.0)	23 (92.0)
25-29	91	61 (67.0)	81 (89.0)
30-39	178	116 (65.2)	153 (86.0)
40-49	140	90 (64.3)	131 (93.6)
50+	181	106 (58.6)	163 (90.1)

Receipt of HIV Care and Treatment Among Self-Reported HIV-Positive Transgender Women	Total Number of Survey Participants <sup>b</sup>	Number (%) Who Visited Health Care Provider About HIV Within One Month After Diagnosis	Number (%) Who Are Currently Taking Antiretrovirals
<b>Race/Ethnicity</b>			
American Indian/Alaska Native	11	5 (45.5)	10 (90.9)
Asian	6	5 (83.3)	6 (100)
Black/African American	322	207 (64.3)	286 (88.8)
Hispanic/Latina <sup>c</sup>	196	130 (66.3)	181 (92.3)
Native Hawaiian/Other Pacific Islander	7	3 (42.9)	6 (85.7)
White	27	16 (59.3)	20 (74.1)
Multiple Races	44	22 (50.0)	40 (90.9)
<b>Total</b>	<b>615</b>	<b>389 (63.3)</b>	<b>551 (89.6)</b>

Source: Table 7 in CDC. HIV Infection, Risk, Prevention, and Testing Behaviors Among Transgender Women—National HIV Behavioral Surveillance, 7 U.S. Cities, 2019–2020. *HIV Surveillance Special Report 27*  . Published April 2021. Accessed September 2021.

Abbreviations: NHBS, National HIV Behavioral Surveillance; PrEP, pre-exposure prophylaxis.

*a* The seven U.S. cities in this report included Atlanta, GA; Los Angeles, CA; New Orleans, LA; New York City, NY; Philadelphia, PA; San Francisco, CA; and Seattle, WA.

*b* Data include all participants who reported having ever received an HIV-positive test result (which may include those who did not have a valid NHBS result, positive or negative, or who did not consent to the HIV test). “Past six months” refers to the 6 months before interview.

*c* Hispanics/Latinas can be of any race.

Showing 1 to 17 of 17 entries